Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACCLAIM-Lp(a) phase 3 trial of lepodisiran for cardiovascular event reduction
MOH_2024-03-26_013208Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2024
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease and cardiac morbidity comparing lepodisiran sodium subcutaneous with placebo subcutaneous (2 arms). Started Mar 2024; status: active, not recruiting.
02
Drugs
lepodisiran
03
Conditions
atherosclerotic diseasecardiac morbidity
Beyond the preview
Go deeper on MOH_2024-03-26_013208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-03-26_013208.